Berberine and Its More Biologically Available Derivative, Dihydroberberine, Inhibit Mitochondrial Respiratory Complex I
Diabetes2008Vol. 57(5), pp. 1414–1418
Citations Over TimeTop 1% of 2008 papers
Nigel Turner, Jing-Ya Li, Alison K. Gosby, Sabrina Wai-Chi To, Zhe Cheng, Hiroyuki Miyoshi, Makoto M. Taketo, Gregory J. Cooney, Edward W. Kraegen, David E. James, Li-Hong Hu, Jia Li, Ji-Ming Ye
Abstract
Complex I of the respiratory chain represents a major target for compounds that improve whole-body insulin sensitivity through increased AMPK activity. The identification of a novel derivative of BBR with improved in vivo efficacy highlights the potential importance of BBR as a novel therapy for the treatment of type 2 diabetes.
Related Papers
- → Prenylated chalcones 4‐hydroxyderricin and xanthoangelol stimulate glucose uptake in skeletal muscle cells by inducing GLUT4 translocation(2010)52 cited
- → Kaempferitrin inhibits GLUT4 translocation and glucose uptake in 3T3-L1 adipocytes(2009)37 cited
- → The interaction of auraptene and other oxyprenylated phenylpropanoids with glucose transporter type 4(2017)16 cited
- → Poster 71: Goldmann Tonometer Calibration Changes Over Time(2008)1 cited
- → Faculty Opinions recommendation of Thirty sweet years of GLUT4.(2020)